Chardan analyst Geulah Livshits lowered the firm’s price target on Century Therapeutics (IPSC) to $11 from $17 and keeps a Buy rating on the shares after the company reported Q3 results and highlighted updated interim data from the ongoing phase I ELiPSE-1 trial for CNTY-101 in non-Hodgkin lymphoma. Century also announced that it is conducting a strategic review of its pre-clinical pipeline following the acquisition of Clade Therapeutics earlier this year, though the firm is citing the company’s limited visibility on pipeline programs beyond ‘101 ahead of the Q1 update, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics price target lowered to $5 from $9 at H.C. Wainwright
- Century Therapeutics Reports Q3 Results & Strategic Updates
- Century Therapeutics reports Q3 EPS (37c), consensus (45c)
- Century Therapeutics expects cash to support operations into 2H26
- Century Therapeutics sees FY24 GAAP operating expenses $150M-$160M